<![CDATA[Biotek-snakken — December 2017]]>
Link Preview Image
Siden findes ikke

favicon

(borsen.dk)

]]>https://dev.proinvestor.com/forum/topic/401367/biotek-snakken-december-2017RSS for NodeMon, 08 Jun 2026 16:39:35 GMTMon, 18 Dec 2017 17:43:28 GMT60<![CDATA[Reply to Biotek-snakken — December 2017 on Tue, 26 Dec 2017 08:36:48 GMT]]>no access to this article yet! ....

]]>https://dev.proinvestor.com/forum/post/8056871https://dev.proinvestor.com/forum/post/8056871Tue, 26 Dec 2017 08:36:48 GMT<![CDATA[Reply to Biotek-snakken — December 2017 on Thu, 21 Dec 2017 19:31:15 GMT]]>Min nye analyse på Nuevolution: http://www.proinvestor.com/aktieanalyser/255/

]]>https://dev.proinvestor.com/forum/post/8056876https://dev.proinvestor.com/forum/post/8056876Thu, 21 Dec 2017 19:31:15 GMT<![CDATA[Reply to Biotek-snakken — December 2017 on Wed, 20 Dec 2017 22:05:44 GMT]]>Lidt om outlook for Exelixis i denne artikel https://finance.yahoo.com/news/exelixis-apos-cabometyx-takes-aim-190000425.html

]]>https://dev.proinvestor.com/forum/post/8056875https://dev.proinvestor.com/forum/post/8056875Wed, 20 Dec 2017 22:05:44 GMT<![CDATA[Reply to Biotek-snakken — December 2017 on Wed, 20 Dec 2017 06:45:28 GMT]]>Celestial studiet i HCC opnåede jo også primary endpoint, så det går virkelig godt for dem, men kommer der mere?

]]>https://dev.proinvestor.com/forum/post/8056874https://dev.proinvestor.com/forum/post/8056874Wed, 20 Dec 2017 06:45:28 GMT<![CDATA[Reply to Biotek-snakken — December 2017 on Wed, 20 Dec 2017 06:41:06 GMT]]>Næste skridt for EXEL indenfor RCC bliver kombi studierne med Opdivo, men hvad ligger der ellers og venter?

]]>https://dev.proinvestor.com/forum/post/8056872https://dev.proinvestor.com/forum/post/8056872Wed, 20 Dec 2017 06:41:06 GMT<![CDATA[Reply to Biotek-snakken — December 2017 on Wed, 20 Dec 2017 06:39:54 GMT]]>Er det den miserable GEN kurs du tænker på Sukker? Eller hvilke omstændigheder? Man må sige at EXEL bare performer rigtig godt, ligesom de har gjort det i lang tid

]]>https://dev.proinvestor.com/forum/post/8056873https://dev.proinvestor.com/forum/post/8056873Wed, 20 Dec 2017 06:39:54 GMT<![CDATA[Reply to Biotek-snakken — December 2017 on Wed, 20 Dec 2017 03:38:00 GMT]]>Det var sørme en lækker nyhed - specielt også set i lyset af omstændighederne.

]]>https://dev.proinvestor.com/forum/post/8056868https://dev.proinvestor.com/forum/post/8056868Wed, 20 Dec 2017 03:38:00 GMT<![CDATA[Reply to Biotek-snakken — December 2017 on Tue, 19 Dec 2017 21:58:58 GMT]]>Endnu en god nyhed fra stærke EXEL: Cabozantinib godkendt til frontline RCC 2 mdr før deadline https://seekingalpha.com/news/3319230-fda-oks-exelixis-cabometyx-first-line-kidney-cancer-shares-ahead-3-percent?app=1&uprof=45&dr=1#email_link

]]>https://dev.proinvestor.com/forum/post/8056870https://dev.proinvestor.com/forum/post/8056870Tue, 19 Dec 2017 21:58:58 GMT<![CDATA[Reply to Biotek-snakken — December 2017 on Mon, 18 Dec 2017 19:41:40 GMT]]>Nogen, der kigget på Pieris (PIRS)? De kunne godt se lidt spændende ud på et par
års sigt...

]]>https://dev.proinvestor.com/forum/post/8056869https://dev.proinvestor.com/forum/post/8056869Mon, 18 Dec 2017 19:41:40 GMT